It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Glaucoma of which primary open angle glaucoma (POAG) constitutes 75%, is the second leading cause of blindness. Elevated intra ocular pressure and Nitric oxide synthase (NOS) dysfunction are hallmarks of POAG. We analyzed clinical data, cytokine profile, ATP level, metabolomics and GEO datasets to identify features unique to POAG. N9 microglial cells are used to gain mechanistic insights. Our POAG cohort showed elevated ATP in aqueous humor and cytokines in plasma. Metabolomic analysis showed changes in 21 metabolites including Dimethylarginine (DMAG) and activation of tryptophan metabolism in POAG. Analysis of GEO data sets and previously published proteomic data sets bins genes into signaling and metabolic pathways. Pathways from reanalyzed metabolomic data from literature significantly overlapped with those from our POAG data. DMAG modulated purinergic signaling, ATP secretion and cytokine expression were inhibited by N-Ethylmaleimide, NO donors, BAPTA and purinergic receptor inhibitors. ATP induced elevated intracellular calcium level and cytokines expression were inhibited by BAPTA. Metabolomics of cell culture supernatant from ATP treated sets showed metabolic deregulation and activation of tryptophan metabolism. DMAG and ATP induced IDO1/2 and TDO2 were inhibited by N-Ethylmaleimide, sodium nitroprusside and BAPTA. Our data obtained from clinical samples and cell culture studies reveal a strong association of elevated DMAG, ATP, cytokines and activation of tryptophan metabolism with POAG. DMAG mediated ATP signaling, inflammation and metabolic remodeling in microglia might have implications in management of POAG.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Sri Sathya Sai Institute of Higher Learning, Prasanthi Nilayam, Disease Biology Lab, SSSIHL-Agilent Center for Excellence in Multiomics and Cell Sciences, Dept. of Biosciences, Anantapur, India
2 Sri Sathya Sai Institute of Higher Learning, Prasanthi Nilayam, Disease Biology Lab, SSSIHL-Agilent Center for Excellence in Multiomics and Cell Sciences, Dept. of Biosciences, Anantapur, India; CMS College, Dept. of Botany/Biotechnology, Kottayam, India
3 University of Leeds, Leeds Institute of Cardiovascular and Metabolic Medicine, School of Medicine, Leeds, UK
4 Sri Sathya Sai Institute of Higher Learning, Prasanthi Nilayam, SSSIHL-Agilent Center for Excellence in Multiomics and Cell Sciences, Dept. of Chemistry, Anantapur, India; Phenomenex India, Hyderabad, India
5 Sri Sathya Sai Institute of Higher Medical Sciences, Prasanthi Gram, Department of Ophthalmology, Anantapur, India
6 Agilent Technologies Ltd., Application Division, Bengaluru, India